References
- Abdel-Aziz AA-M, Asiri YA, El-Azab AS, Al-Omar MA, Kunieda T. 2011. Tadalafil. In: Brittain HG, editor. Profiles of drug substances, excipients, and related methodology. Amsterdam: Elsevier Inc.; p. 287–329.
- Daugan A, Grondin P, Ruault C, de Gouville A-C, Le M, Coste H, Linget JM, Kirilovsky J, Hyafil F, Labaudinière R. 2003. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. J Med Chem. 46:4533–4542.
- Hasegawa T, Saijo M, Ishii T, Nagata T, Haishima Y, Kawahara N, Goda Y. 2008. Structural elucidation of a tadalafil analogue found in a dietary supplement. J Food Hyg Soc Jpn (Shokuhin Eiseigaku Zasshi). 49:311–315.
- Huang Y-C, Lee H-C, Lin Y-L, Li C-Y, Tsai C-F, Cheng H-F. 2016. Separation and identification of a novel tadalafil analogue adulterant in a dietary supplement. Food Addit Contam Part A. 33:179–185.
- Lin M-C, Liu Y-C, Lin Y-L, Lin J-H. 2009. Identification of a tadalafil analogue adulterated in a dietary supplement. J Food Drug Anal. 17:451–458.
- Patel DN, Li L, Kee C-L, Ge X, Low M-Y, Koh H-L. 2014. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges. J Pharm Biomed Anal. 87:176–190.
- Toomey VM, Litzau JJ, Flurer CL. 2012. Isolation and structural characterization of two tadalafil analogs found in dietary supplements. J Pharm Biomed Anal. 59:50–57.
- Zhang G, Yu Y, Wu X, Li J. 2014. Separation and structural elucidation of a new tadalafil analogue diethylaminopretadalafil included as an adulterant in a dietary supplement. J Pharm Biomed Anal. 94:210–214.